Last update 19 Sep 2024

MALT1 x FABP5

Basic Info

Related Targets
MALT1FABP5

Related

1
Drugs associated with MALT1 x FABP5
XL-114
Target
FABP5 x MALT1
Mechanism
FABP5 inhibitors [+1]
Active Org.
Aurigene Oncology Ltd.Aurigene Oncology Ltd. [+1]
Originator Org.
Aurigene Oncology Ltd.Aurigene Oncology Ltd.
Active Indication
Non-Hodgkin Lymphoma [+2]
Inactive Indication
Chronic Lymphocytic Leukemia [+3]
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with MALT1 x FABP5
NCT05144347
/ TerminatedPhase 1
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma
100 Clinical Results associated with MALT1 x FABP5
Login to view more data
100 Translational Medicine associated with MALT1 x FABP5
Login to view more data
0 Patents (Medical) associated with MALT1 x FABP5
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free